



HAL
open science

Differences in HIV cure clinical trial preferences of French people living with HIV and physicians in the ANRS-APSEC study: a discrete choice experiment

Christel Protière, Michael Arnold, Marion Fiorentino, Lisa Fressard, Jean Lelièvre, Mohamed Mimi, Francois Raffi, Marion Mora, Laurence Meyer, Luis Sagaon-Teyssier, et al.

► To cite this version:

Christel Protière, Michael Arnold, Marion Fiorentino, Lisa Fressard, Jean Lelièvre, et al.. Differences in HIV cure clinical trial preferences of French people living with HIV and physicians in the ANRS-APSEC study: a discrete choice experiment. *Journal of the International AIDS Society*, 2020, 23 (2), pp.e25443. 10.1002/jia2.25443 . hal-02496166

HAL Id: hal-02496166

<https://amu.hal.science/hal-02496166>

Submitted on 7 Jun 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution| 4.0 International License

RESEARCH ARTICLE

Differences in HIV cure clinical trial preferences of French people living with HIV and physicians in the ANRS-APSEC study: a discrete choice experiment

Christel Protiere^{1,2,§} , Michael Arnold³, Marion Fiorentino^{1,2}, Lisa Fressard², Jean D Lelièvre^{4,5,6}, Mohamed Mimi^{1,2}, François Raffi⁷, Marion Mora^{1,2}, Laurence Meyer⁸, Luis Sagaon-Teyssier^{1,2}, David Zucman⁹, Marie Préau¹⁰, Olivier Lambotte^{11,12,13,14}, Bruno Spire^{1,2}, Marie Suzan-Monti^{1,2} and the APSEC Study Group

[§]Corresponding author: Christel Protière, Aix Marseille Univ – SESSTIM, 19-21 Bd Jean Moulin, 13005 Marseille, France. Tel: +33 413 732 286. (christel.protiere@inserm.fr)

Abstract

Introduction: Despite the advent of HIV cure-related clinical trials (HCRCT) for people living with HIV (PLWH), the risks and uncertainty involved raise ethical issues. Although research has provided insights into the levers and barriers to PLWH and physicians' participation in these trials, no information exists about stakeholders' preferences for HCRCT attributes, about the different ways PLWH and physicians value future HCRCT, or about how personal characteristics affect these preferences. The results from the present study will inform researchers' decisions about the most suitable HCRCT strategies to implement, and help them ensure ethical recruitment and well-designed informed consent.

Methods: Between October 2016 and March 2017, a discrete choice experiment was conducted among 195 virally controlled PLWH and 160 physicians from 24 French HIV centres. Profiles within each group, based on individual characteristics, were obtained using hierarchical clustering. Trade-offs between five HCRCT attributes (trial duration, consultation frequency, moderate (digestive disorders, flu-type syndrome, fatigue) and severe (allergy, infections, risk of cancer) side effects (SE), outcomes) and utilities associated with four HCRCT candidates (latency reactivation, immunotherapy, gene therapy and a combination of latency reactivation and immunotherapy), were estimated using a mixed logit model.

Results: Apart from severe SE – the most decisive attribute in both groups – PLWH and physicians made different trade-offs between HCRCT attributes, the latter being more concerned about outcomes, the former about the burden of participation (consultation frequency and moderate SE). These different trades-offs resulted in differences in preferences regarding the four candidate HCRCT. PLWH significantly preferred immunotherapy, whereas physicians preferred immunotherapy and combined therapy. Despite the heterogeneity of characteristics within the PLWH and physician profiles, results show some homogeneity in trade-offs and utilities regarding HCRCT.

Conclusions: Severe SE, not outcomes, was the most decisive attribute determining future HCRCT participation. Particular attention should be paid to providing clear information, in particular on severe SE, to potential participants. Immunotherapy would appear to be the best HCRCT candidate for both PLWH and physicians. However, if the risk of cancer could be avoided, gene therapy would become the preferred strategy for the latter and the second choice for the former.

Keywords: HIV eradication/remission; therapeutic HIV vaccine trial; social sciences; discrete choice experiment; preferences; ethics; clinical trial design recommendations; mixed logit model

Additional information may be found under the Supporting Information tab for this article.

Received 3 May 2019; Accepted 4 December 2019

Copyright © 2020 The Authors. *Journal of the International AIDS Society* published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

1 | INTRODUCTION

HIV cure research, a desired but risky and “uncomfortable” innovation [1], raises several ethical questions [2–6]. More specifically, to test the effectiveness of new HIV cure-related clinical trials (HCRCT), clinicians must recruit persons living

with HIV (PLWH) who are successfully managing their health and the virus. Trial participation may have negative consequences for PLWH, including side effects (SE), increased transmission risk during antiretroviral treatment interruption (ATI) [7], disturbances to balanced lifestyles, and additional constraints and burdens related to the therapeutic strategies

being tested. Currently, the expected benefit of participation is not remission or eradication, but an ATI [8–10] of only a few months for a low proportion of participants. This suggests a poor risk-benefit ratio, which raises concerns about HCRCT participation coercion and consent [11].

The literature provides mixed findings regarding the willingness of PLWH to participate in HCRCT [12]. In surveys, most respondents have expressed strong motivation and willingness [3,13,14]. However, qualitative interviews indicate less interest [4,15–18]. There may be several reasons for this, including differences in methodology and in questions posed, as well as discrepancies between declared intentions and actual behaviour [19].

HIV altruism is one important motivator influencing willingness to participate in HCRCT [3,12,15,18], reflecting the historical advocacy and joint mobilization of PLWH in response to HIV epidemic [1,2,20,21]. Altruistic-based benefits, such as participating in research for the benefit of future generations, have been shown to be part of the value associated with some health programmes [22–24]. As a result, altruism should be considered a benefit induced by participation in HCRCT. Fear of SE and of the increased risk of transmission during ATI, the burden associated with appointments and clinical examinations, the poor expected personal clinical benefits, and uncertainty in terms of efficiency and SE, have all been shown to negatively influence willingness to participate [3,12,14,15,18]. However, to the best of our knowledge, no study has investigated how stakeholders weigh different trial attributes when deciding about HCRCT participation.

Whenever possible, the type of HCRCT implemented should reflect PLWH trial preferences [13,15,25]. Accordingly, a better understanding of how PLWH assess and make trade-offs between different HCRCT attributes can provide useful insights about the best trial designs to implement, with a view to ensuring adequate numbers of participants to explore HCRCT effectiveness. Physicians [4,12,15,18] and physician-patient relationships [1,26] can also influence PLWH motivations to participate. As physicians are not all equally motivated to propose HCRCT, it is important to also compare and contrast their preferences with those of PLWH [12,14,18].

An important role of social science is to inform real-world decision making [27,28]. The cross-sectional ANRS-APSEC study, nested inside the IAS “Towards an HIV cure,” enabled us to explore, for the first time, the following three questions: (1) What trial design attributes most influence PLWH and physician trial acceptability? (2) To what extent do PLWH and physicians value candidate HCRCT differently? (3) How do differences within the PLWH and physician populations affect these preferences? Our results may help HCRCT researchers choose the most suitable HCRCT strategies to implement when designing trials, with a view to ensuring adequate participation numbers and effective HCRCT-related communication strategies.

2 | METHODS

The survey received ethical approval from the CCTIRS (Advisory Committee on Information Processing of Research Information in the Field of Health) and the CNIL (National Commission for Computing and Liberties).

2.1 | Survey population

Between October 2016 and March 2017, in 24 HIV centres across France, all HIV physicians and PLWH who had a follow-up consultation during a dedicated week, and met eligibility criteria similar to those for inclusion in future HCRCT (≥ 18 years old, stable ART regimen ≥ 6 months, undetectable viral load ≥ 3 years, and a CD4 cell count > 500 cells/mm³) were invited to participate in a discrete choice experiment (DCE).

All respondents received an information letter and provided written consent. Trained interviewers administered a face-to-face computer-assisted questionnaire.

2.2 | Development of HCRCT attributes to be evaluated and the DCE surveys

The underlying assumptions in a DCE are that healthcare interventions can be described by their attributes (or characteristics) and that a respondent's valuation of an intervention depends on the level of each of these attributes [29–32]. In DCE, respondents are presented with several pairs of hypothetical designs. Each time a pair is presented, respondents choose the design they would prefer, according to attribute levels. For example, in our study, a hypothetical HCRCT design may have more severe side effects (SE) but the best outcome (the outcome being defined as a given duration of antiretroviral treatment interruption (ATI) for a given percentage of participants) compared with another design (Table S1). By presenting an appropriate number of comparisons, we were able to infer how much a given attribute influenced respondents' decisions.

Based on previous results from the ANRS-APSEC study, the literature [10,12,18] and consensus between the physicians on the study's scientific committee, five HCRCT attributes, each with either two or three levels, were retained for the DCE (Table 1).

To reduce respondent burden while ensuring maximum information, to estimate relative preference coefficients for all attributes and levels, we used a partial factorial design supplied in R software package *support*. CEs [33]. This resulted in a d-efficient design consisting of 13 pair comparisons [34–36] with an 83% D-efficiency score. Each of the 13 fixed pairs were presented to respondents in a randomized order to avoid anchor bias. The choice set was presented in an unlabelled form to avoid bias due to social representations and to ensure attention was given to the attributes [37].

Apart from the DCE, the face-to-face questionnaire collected data on sociodemographic characteristics, experience with HIV and ART, previous experience with HIV clinical trial participation, viewpoint regarding HCRCT, and sources used to gather HIV information. The PLWH and physician questionnaires were identical except that the former included the post-traumatic growth (PTG) scale [38,39]. Post traumatic disorder being associated with voluntary treatment interruption [40].

In collaboration with the French NGO AIDES, a pilot survey was conducted with 10 PLWH, resulting in some questions being removed or reworded. The DCE exercise was well understood and mobilized PLWH interest.

Table 1. Description of attributes and their levels

Attribute	Level	Label	Description
1. Trial duration	1	Short	6-9 months
	2	Long	15 to 18 months
2. Consultation frequency	1	Weekly	Weekly
	2	Monthly	Monthly
3. Moderate SE (1% to 10%, few days)	1	Low	Digestive disorders (nausea, vomiting)
	2	Intermediate	Flu-type syndrome (fever, shivers, stiffness, joint pain)
	3	High	Digestive disorders, flu-type syndrome, fatigue
4. Severe SE (<1/1000)	1	Low	Allergy
	2	Intermediate	Allergy, infections
	3	High	Allergy, infections, risk of cancer a few years later (missing data for estimating how frequent the risk is)
5. Outcomes (ATI duration, % of success)	1	3 to 6 months, 5%	ATI of three to six months, for 5% of patients
	2	6 to 12 months, 10%	ATI of six to twelve months, for 10% of patients

SE, side effects.

2.3 | Statistical and econometrical analyses

To explore the possibility of sample bias, we compared PLWH in our sample with the 638 PLWH from the French representative national VESPA2 cohort [41,42] who met the same inclusion criteria as ours, regarding gender, age, professional status, perceived financial situation, housing occupational status and educational level.

2.3.1 | PLWH and physician profiles

To elicit distinct intragroup respondent profiles for PLWH and physicians, two hierarchical clustering procedures were performed on all variables (Table S2), except those related to DCE, using the SAS (v9.4), SAS Campus Drive, Cary, NC CAHQAL macro-command, developed by the French National Institute for Statistics and Economic Studies [43]. We used the Ward method based on minimum inertia lost. The optimal number of clusters was determined with dendrograms, line plots of the cubic clustering criterion, and line plots of combined pseudo-F and pseudo t^2 statistics.

2.3.2 | Discrete choice experiment

We tested several models for the conjoint analysis of the DCE. First, a conditional logit model [44], which assumes

common preferences for observed attributes; second, a mixed logit (MXL) model [45], which accounts for heterogeneity in the trade-offs between the attribute levels but assumes that preferences between attributes are independent; third, a MXL model which accounts for heterogeneity and correlation in unobserved factors (captured by the error terms). This model was chosen based on Akaike's information criterion (AIC) [46] (results not shown). Analyses were performed using the *clogit* and *mixlogit* commands from Stata/SE 12.1 (Stata Corp LP, College Station, TX).

Two DCE models were estimated, one each for PLWH and physicians (intergroup comparison). To test for preference stability according to differences in respondent characteristics, two additional DCE models were estimated among PLWH and physician profiles (intragroup comparison). Measurement of the utility (value) associated with candidate HCRCT.

Although one would expect the preferred choice to be a hypothetical HCRCT design promising the fewest severe and moderate SE for the best outcome (six to twelve months ATI in 10% of patients), such a trial cannot exist in real life. Physicians from the scientific committee described four candidate HCRCT aimed at achieving a functional cure (long-term control of HIV in the absence of ART), as the only current sterilizing cure (elimination of all HIV-infected cells) option is allogeneic bone marrow transplant [2,5,47-56]. We described the four HCRCT (latent reactivation, immunotherapy, gene therapy and a combination of latency reactivation and immunotherapy) according to attributes and levels (Table S3).

To compare the utility of these four HCRCT, we applied significant estimated coefficients to each one, which were associated with corresponding attribute levels obtained from the PLWH and physician MXL models. A linear transformation was used to associate the lowest utility ($U = 0$) to the hypothetically worst design (attribute levels having the lowest coefficients) and the highest utility ($U = 100$) to the hypothetically best design (attribute levels having the highest coefficients). This linear transformation allowed us to compare the four HCRCT, according to their utility, on a 0 to 100 scale [30,57,58]. 95% confidence intervals were estimated using the delta method [59,60].

3 | RESULTS

3.1 | Characteristics of the surveyed population

All the 195 PLWH (median inclusion = 9/centre) presented to the interviewers agreed to participate in the survey. Three (1.84%) of the 163 physicians (72.8%, median inclusion = 6/centre) who agreed to participate were excluded because they did not complete the DCE exercise.

Women comprised 23.6% of the PLWH sample, with a median (IQR) age of 53 (45 to 61) years, and median experience with HIV of 17 (11 to 25) years. Most (69.7%) considered themselves to be part of the PLWH community, and 41.5% part of the LGBT (lesbian, gay, bisexual, transgender) community. Eighty percent (80.5%) declared their willingness to participate in a HCRCT based on their preferred hypothetical design, as identified by their responses in the DCE.

In contrast to VESPA2 PLWH who met the same criteria, our sample comprised fewer women (33.4% vs. 23.6%, $p < 0.05$) and fewer individuals with less than a high-school

diploma (51.7% vs. 38.5%, $p < 0.01$). No other differences were observed.

Women comprised 51.3% of the physician sample, with a median (IQR) age of 50 (40 to 57) years, and a median (IQR) experience with HIV of 20 (10 to 26) years. The large majority considered themselves to be part of the heterosexual community (80.6%). Almost all (97.5%) declared they would propose the HCRCT based on their preferred hypothetical design.

3.1.1 | PLWH and physician profiles (results of hierarchical clustering)

Three distinct profiles were elicited for both the PLWH and physicians using hierarchical clustering (Table S2), each having three levels of perception of the burden associated with HIV and ART, plus a financial and psychological vulnerability effect for PLWH profiles, and a generational effect for physician profiles.

PLWH profiles

The first PLWH profile, labelled “comfortable & confident,” represented nearly half of the sample (48%). It included a large proportion of financially comfortable PLWH who declared no impact of HIV on their life and no need of moral support, who considered themselves well informed about HIV scientific advances, but who had no previous knowledge of HCRCT. They were confident about the long-term efficiency of current ART and about the possible availability of an HIV cure during their lifetime. They considered research as a way to build on previous generations’ work and were motivated to participate in cure research under certain conditions.

The second profile labelled “moderate” represented 19% of the sample. It included a large proportion of PLWH who considered themselves part of the LGBT community. They felt very concerned about the fact that living with HIV implies living with a secret, the use of condoms, the difficulty of having to take treatment every day, and associated SE.

The third profile, labelled “vulnerable & unconfident” represented 33% of the sample and included large proportions of women, of people co-infected with HCV, of people expressing financial and health vulnerabilities, and people reporting that HIV and ART negatively impacted their lives. They had poorer

self-esteem and a greater need of HIV-related moral support. They were less confident about the long-term efficiency of ART and the availability of an HIV cure during their lifetime.

Physician profiles

The first physician profile, labelled “engaged & patient-centered,” represented half of the sample (53%) and was characterized by a large proportion of physicians engaged in HIV clinical trials in general and HCRCT in particular. They self-defined as heterosexuals and HIV activists and considered that HIV and ART had a strong negative impact on their patients’ lives.

The second and third profiles represented the remaining half of the sample and included a large proportion of physicians who self-reported being part of the LGBT community. They were split between the youngest and least experienced physicians (labelled “least experienced & moderate,” 29%) and the oldest and most experienced physicians (labelled “most experienced & reticent,” 19%). The latter profile more often expressed reticence toward clinical trials in general, and did not believe that ART or HIV induced great difficulties in their patients’ lives. Those in the second profile adopted an intermediate position between the first and the third profiles.

3.2 | Most decisive attributes in the decision to participate in/propose HCRCT (results from the DCE models)

3.2.1 | Intergroup comparison

Figure 1 shows that the most decisive attribute in the decision to participate in/propose HCRCT was the level of severe SE: the lower the level, the higher the willingness to participate/propose (Table S4). Furthermore, severe SE were more important for physicians (allergy: 10.54; allergy, infection: 10.12; $p < 0.001$) than for PLWH (allergy: 4.52; allergy, infections: 3.87; $p < 0.001$). The least decisive attribute for both was trial duration (a short duration being preferred), which was significant only for PLWH (0.79, $p < 0.001$).

With regard to the three other attributes, trade-offs differed between the PLWH and physicians.

For PLWH, the second most decisive attribute was consultation frequency (monthly being preferred: 2.50, $p < 0.001$),

PLWH	Physicians
Severe side effects (vs. high)	
Low, Intermediate (4.52, 3.87)***	(10.54, 10.12)***
Consultation frequency (vs. weekly) Monthly (2.50)***	Outcomes (vs. 3 to 6 m. 5%) 6 to 12 m, 10% (6.77)***
Moderate side effects (vs. high) Low, Intermediate (1.90, 1.34)***	Consultation frequency (vs. weekly) Monthly (4.95)***
Outcomes (vs. 3 to 6 m. 5%) 6 to 12 m, 10% (1.14)***	Moderate side effects (vs. high) Low, Intermediate (3.12)***, 0.94*
Trial duration (vs. long) Short (0.79)***	

Figure 1. Results of the DCE for PLWH and physicians. *** $p < 0.001$, ** $p < 0.05$, * $p < 0.1$.

followed by moderate SE (digestive disorders: 1.90, flu-type syndrome: 1.34; $p < 0.001$) and then outcomes (ATI of six to twelve months, for 10% of patients: 1.14, $p < 0.001$).

For physicians, the second most decisive attribute was outcomes (6.77, $p < 0.001$) followed by consultation frequency (4.95, $p < 0.001$), and then moderate SE (3.12, $p < 0.001$).

3.2.2 | Intragroup comparisons

Between PLWH profiles

For all three PLWH profiles, the three most decisive attributes were severe SE (low and intermediate), followed by consultation frequency, and moderate SE (low) (Figure 2).

The main difference between profiles was the importance given to outcomes, which was a more decisive attribute for the *comfortable & confident* (1.57, $p < 0.001$) than for the *vulnerable & unconfident* (1.02, $p = 0.007$) and *moderate* (0.99, $p = 0.013$) PLWH. For the *comfortable & confident* and *vulnerable & unconfident* PLWH, trial duration was the least decisive attribute, whereas for *moderate* PLWH it was outcomes.

Between physician profiles

For all physician profiles, the most significant decisive attribute was severe SE while the least significant was moderate SE. The second most decisive attribute for the *most*

experienced & reticent physicians was consultation frequency, whereas for the other two profiles it was outcomes (Figure 3).

3.3 | Utilities associated with the four candidate HCRCT

3.3.1 | HCRCT utilities for PLWH and physicians

For PLWH, the order of preference was immunotherapy (77.03 (95% CI 71.89 to 82.17)), latency reactivation (60.41 (55.89 to 64.93)), combined therapy (46.16 (40.89 to 51.43)) and gene therapy (28.05 (24.00 to 32.10)), with significant differences between all four candidate HCRCT (Figure 4).

For physicians, combined therapy (66.55 (60.56 to 72.55)) and immunotherapy (61.05 (58.43 to 63.68)) were significantly preferred to latency reactivation (52.16 (46.99 to 57.33)), which in turn was significantly preferred to gene therapy (38.95 (28.65 to 40.60)).

Gene therapy implied the highest level of severe SE, including a risk of cancer within a few years for an unknown number of cases (Table S3). Consequently, it was significantly less preferred, irrespective of the population considered, and despite physicians valuing it significantly higher than PLWH. We then modelled gene therapy considering the intermediate level of severe SE (allergy, infections), instead of the highest

<i>Comfortable & confident</i>	<i>Moderate</i>	<i>Vulnerable & unconfident</i>
Severe side effects (vs. high)		
Low, Intermediate (4.72, 4.06)***	(4.54, 3.90)***	(4.77, 4.29)***
Consultation frequency (vs. weekly)		
Monthly (3.29***)	(2.47***)	(2.38***)
Moderate side effects (vs. High)		
Low (2.16***)	(2.12***)	(1.81***)
Outcomes (vs. 3 to 6, 5% 6 to 12 m, 10% (1.57***)	Moderate side effects (vs. High) Intermediate (1.24**)	(1.30**)
Moderate side effects Intermediate (1.29**)	Duration of the trial Short (1.18***)	Outcomes 6 to 12 m, 10% (1.02**)
Trial duration (vs. long) Short (0.95***)	Outcomes 6 to 12 m, 10% (0.99**)	Trial duration Short (0.63**)

Figure 2. Results of the DCE for the three PLWH profiles. *** $p < 0.001$, ** $p < 0.05$, * $p < 0.1$.

<i>Engaged & patient-centred</i>	<i>Least experienced & moderate</i>	<i>Most experienced & reticent</i>
Severe side effects (vs. high)		
Low, Intermediate (15.45, 14.52)***	(11.64, 9.52)***	(7.10, 7.87)***
Outcomes (vs. 3-6, 5%) 6 to 12 m, 10%(9.45***)	(5.86***)	Consultation frequency Monthly (4.74***)
Consultation frequency (vs. weekly) Monthly (6.91***)	(5.10***)	Outcomes 6 to 12 m, 10% (4.03***)
Moderate side effects (vs. high)		
Low, intermediate(5.03 ***, 2.48**)	(3.78***, 1.53*)	(2.65***, ns)

Figure 3. Results of the DCE for the three physician profiles. *** $p < 0.001$, ** $p < 0.05$, * $p < 0.1$.




Figure 4. Utilities of four candidate HCRCT according to PLWH and physicians.

level (allergy, infections, risk of cancer). In this case, gene therapy became the most preferred HCRCT for the physicians (78.8 (73.8 to 83.9)) and the second most preferred for the PLWH (63.7 (58.2 to 69.1)).

3.3.2 | HCRCT utilities for each of the PLWH and physician profiles

The preference order for the four candidate HCRCT was similar for the three intragroup profiles for both PLWH and physicians, but differed in terms of intensity (Figure 5). For example, immunotherapy (71.24 (61.67 to 80.80)) and latency reactivation (62.66 (54.55 to 70.78)) were significantly preferred to combined therapy (43.82 (35.15 to 52.49)) and gene therapy (29.27 (22.05 to 36.49)) for the *moderate* PLWH profile. For the *vulnerable & unconfident* PLWH profile, immunotherapy (79.67 (70.23 to 89.12)), latency reactivation (63.38 (56.02 to 70.74)) and combined therapy were (50.08 (41.65 to 58.50)) significantly preferred to gene therapy (26.69 (19.33 to 34.05)).

Among physicians, the *most experienced & reticent* profile stood out as there was no significant difference between immunotherapy (61.42 (52.45 to 70.40)), combined therapy

(61.69 (55.14 to 68.25)) and latency reactivation (54.50 (45.84 to 63.17)).

4 | DISCUSSION

Despite major reductions in HIV-related mortality and morbidity thanks to antiretroviral treatment (ART), as yet no cure exists. The lack of universal access to ART, new infections, toxicities related to ART, and the need for life-long treatment all highlight the huge importance of finding a cure. HIV cure research requires active participation of person living with HIV (PLWH) and their physicians. In this context, the ANRS-APSEC survey allowed us to elicit the preferences of these stakeholders regarding four candidate HIV Cure Related Clinical Trial (HCRCT): immunotherapy, latency reactivation, a combination of the two former, and gene therapy.

Our results showed that PLWH and physicians made different trade-offs between five HCRCT attributes. Despite *outcomes* (a given duration of antiretroviral treatment interruption for a given percentage of participants) being more important for physicians than for PLWH, it was not the most decisive attribute to participate in/propose a HCRCT. The




Figure 5. Utilities of four candidate HCRCT according to PLWH and physician profiles.

most decisive attribute for both groups was *severe Side Effects (SE)*, having greater importance for physicians, probably because PLWH trusted them [12,18,26]. The biggest difference in trade-offs was that physicians were more concerned about *outcomes* whereas PLWH were more concerned about their quality of life (*consultation frequency* and *moderate SE*). In line with previous research [3,12,15,18], this result might indicate that PLWH motivations to participate were more altruistic than individual. It also underlines the need for physicians to consider moderate SE and not only severe SE. Despite the heterogeneity of characteristics within the PLWH and physician profiles, trade-offs they made were relatively homogeneous. However, the *comfortable & confident* PLWH profile placed greater importance on *outcomes* (reflecting the physician preference hierarchy) than the other two PLWH profiles. This may be explained by their better life conditions and less worry regarding HCRTC-related constraints. On the contrary, the *most experienced & reticent* physician profile placed greater importance on *consultation frequency* (reflecting the PLWH preference hierarchy) than the other two physician profiles.

The differences in PLWH and physicians' trades-offs resulted in different preferences regarding HCRCT. PLWH significantly preferred immunotherapy whereas physicians preferred combined therapy and immunotherapy. Consequently, immunotherapy seemed to be the best HCRCT candidate. On the contrary, gene therapy was the least preferred HCRCT, because of the associated risk of cancer, and probably also because of the uncertainty related to this risk. Aversion to uncertainty was observed in previous analyses [12,18]. In terms of the profiles, the order of preference for the HCRCT was similar for both PLWH and physicians.

4.1 | Strengths and limitations

Our sample comprised not only men who have sex with men – which is the population most studied in previous surveys – but also women and heterosexuals meeting the clinical criteria for inclusion in HCRCT. However, women and those with less than a high-school diploma are underrepresented compared to PLWH from VESPA2 [41,42]. Unfortunately, we could not evaluate whether this was due to chance related to consultation scheduling, or due to physicians suggesting participation in HCRCT less often to these subgroups [49]. The physician sample comprised professionals familiar with HIV research, but not necessarily HIV cure research. This enabled heterogeneous viewpoints to be considered.

In addition to the four candidate HCRCT selected in this survey, the results of the DCE allowed us to estimate preferences for any HCRCT. Of course the five trial attributes are not enough to document the complexity of an HCRCT. However, they were selected as they were identified as the most decisive attributes in the previous steps of the ANRS-APSEC survey [12,18]. Another attribute – exchange of information before and during the trial – was seen to be important [12], but adding this additional attribute would have led to an overly complex factorial design, thereby necessitating a very large sample. Moreover if future studies consider sterilizing cure, another important attribute to include will be the difference between remission and cure.

5 | CONCLUSIONS

Despite the innovative context of HIV cure research, we found that severe side effects rather than outcomes were the most important attribute for both PLWH and physicians when deciding to participate in/propose an HIV Cure Related Clinical Trial (HCRCT). As a result, particular attention should be paid to provide clear information to potential participants, in particular regarding severe side effects, and to provide feedback about the results during the trial.

Our results suggest that immunotherapy is the best candidate HCRCT for PLWH and physicians. However, if the risk of cancer could be avoided, gene therapy would become the preferred HCRCT for physicians and the second choice for PLWH. Future surveys should be conducted in real-world situations to compare and contrast declared intention with real behaviour.

AUTHORS' AFFILIATIONS

¹INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Aix Marseille Univ, Marseille, France; ²ORS PACA, Observatoire régional de la santé Provence-Alpes-Côte d'Azur, Marseille, France; ³Informing Change, Berkeley, CA, USA; ⁴INSERM, Créteil, France; ⁵Faculté de médecine, Université Paris Est, Créteil, France; ⁶Vaccine Research Institute, Créteil, France; ⁷Department of Infectious Diseases, Hôtel-Dieu Hospital - INSERM CIC 1413, Nantes University Hospital, Nantes, France; ⁸Département d'épidémiologie, INSERM, U1018, Université Paris-Sud 11, AP-HP, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France; ⁹Hôpital Foch, service de médecine interne, Suresnes, France; ¹⁰GREPS Lyon 2 Université, Bron, France; ¹¹Assistance Publique - Hôpitaux de Paris, Hôpital Bicêtre, Service de Médecine Interne et Immunologie clinique, Le Kremlin-Bicêtre, France; ¹²Immunology of Viral Infections and Autoimmune Diseases, INSERM, U1184, Le Kremlin-Bicêtre, France; ¹³UMR 1184, Université Paris Sud, Le Kremlin-Bicêtre, France; ¹⁴CEA, DSV/IMETI, IDMIT, Fontenay-aux-Roses, France

COMPETING INTERESTS

The authors have no competing interests to declare.

AUTHORS' CONTRIBUTIONS

CP, MaM, OL, MSM and BS implemented this work. LF and MoM led the analysis under the supervision of LST and CP. The manuscript was written collaboratively between CP, MA, LF and OL with input from DZ, FR, JDL, LM, MF, MP and BS. MaM provided ongoing support to design and perform data collection. All authors have read and approved the final manuscript.

ABBREVIATIONS

ART, antiretroviral treatment; ATI, antiretroviral treatment interruption; DCE, discrete choice experiment; HCRCT, HIV Cure Related Clinical Trial; HCV, hepatitis C virus; LGBT, lesbian, gay, bisexual, transgender; PLWH, person living with HIV; SE, side effects.

ACKNOWLEDGEMENTS

We thank all the participants, PLWH and members of the following centres: Aix en Provence (Centre Hospitalier Général), Avignon (Centre Hospitalier Henri Duffaut), Bordeaux (Hôpital Pellegrin, Hôpital Saint André), Créteil (Hôpital Intercommunal, Hôpital Henri Mondor), Dijon (Hôpital Du Bocage), Kremlin-Bicêtre (Hôpital De Bicêtre), Lyon (Hôpital Edouard Herriot, Hôpital De La Croix Rousse), Marseille (Hôpital Ste-marguerite), Nantes (Hôpital Hôtel-Dieu), Paris (Hôpital Saint Antoine, Hôpital Pitié-Salpêtrière, Hôpital Lariboisière, Hôtel Dieu, Hôpital Bichat, G. H. Pitié Salpêtrière, Hôpital Lariboisière, Hôtel Dieu, Hôpital Tenon), Rennes (CHRU Pontchaillou), Suresnes (Hôpital Foch), Toulon (Hôpital Sainte Musse), Toulouse (Hôpital Purpan), Tourcoing (Hôpital Gustave Dron). We thank the members of the APSEC scientific committee for their advice: J. Barbot, F. Barré-Sinoussi, A. Chéret, P. Delobel, V. Doré, S. Fainzang, C. Gasiglia, C. Gauzente, J. Ghosn, C. Goujard, O. Lambotte, J.-D. Lelièvre, A. Mennecier, L. Meyer,

M. Mora, M. Préau, C. Protière, A. L. Ross, C. Rouzioux, B. Spire, M. Suzan-Monti. We also thank the SESSTIM-ORS PACA logistic platform: G. Maradan, F. Prestigiaco, E. Parizi. Finally, we thank Jude Sweeney for revising and editing the English version of the manuscript and the anonymous referees for their suggestions that helped to improve the manuscript.

APSEC Study Group: Pr J.F. Bergmann, Pr J. Blacher, Pr A.P. Blanc, Pr P. Delobel, Pr P.M. Girard, Pr C. Goujard, Pr C. Katlama, Dr I. De Lacroix, Dr A. Lefeuvre, Pr J.D. Lelièvre, Dr G. Lepeu, Pr C. Michelet, Pr J.M. Molina, Pr P. Morlat, Pr D. Peyramond, Pr L. Piroth, Pr I. Poizot-Martin, Pr F. Raffi, Pr J.M. Ragnaud, Pr E. Senneville, Pr L. Weiss, Pr Y. Yazdanpanh, Dr D. Zucman.

FUNDING

The ANRS-APSEC survey was supported by a grant (convention number 14697) from ANRS (France Recherche Nord & sud Sida-hiv Hépatites).

REFERENCES

1. Protière C, Préau M, Doumergue M, Mora M, Lambotte O, Spire B, et al. Will CURE trials introduce an uncomfortable revolution in the field of HIV research? *HIV Clin Trials*. 2017;18(4):174–5.
2. Barré-Sinoussi F, Ross AL, Delfraissy J-F. Past, present and future: 30 years of HIV research. *Nat Rev Microbiol*. 2013;11(12):877–83.
3. Arnold MP, Evans D, Vergel N. Recruitment and ethical considerations in HIV cure trials requiring treatment interruption. *J Virus Erad*. 2015;1(1):43–8.
4. Chu CE, Wu F, He X, Ma Q, Cheng Y, Cai W, et al. Exploring the social meaning of curing HIV: a qualitative study of people who inject drugs in Guangzhou, China. *AIDS Res Hum Retroviruses*. 2015;31(1):78–84.
5. Kuritzkes DR. Why cure, why now? *J Med Ethics*. 2017;43(2):67–70.
6. *J Med Ethics*. 43(2) [Internet]. 2017 Feb 1 [cited 2017 Feb 8]. Available from: <http://jme.bmj.com/content/43/2>
7. Palich R, Ghosn J, Chaillon A, Boilet V, Nere M-L, Chaix M-L, et al. Viral rebound in semen after antiretroviral treatment interruption in an HIV therapeutic vaccine double-blind trial. *AIDS*. 2019;33(2):279–84.
8. Chun T-W, Eisinger RW, Fauci AS. Durable control of HIV infection in the absence of antiretroviral therapy: opportunities and obstacles. *JAMA*. 2019;322(1):27–8.
9. Eyal N, Deeks SG. Risk to nonparticipants in HIV remission studies with treatment interruption: a symposium. *J Infect Dis*. 2019;220 Suppl. 1:S1–4.
10. Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, et al. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting. *Lancet HIV*. 2019;6(4):e259–68.
11. Kumar R. Contractualist reasoning, HIV cure clinical trials, and the moral (ir)relevance of the risk/benefit ratio. *J Med Ethics*. 2017;43(2):124–7.
12. Protière C, Spire B, Mora M, Poizot-Martin I, Préau M, Doumergue M, et al. Patterns of patient and healthcare provider viewpoints regarding participation in HIV cure-related clinical trials. Findings from a multicentre French survey using Q methodology (ANRS-APSEC). *PLoS ONE*. 2017;12:e0187489.
13. Simmons R, Kall M, Collins S, Cairns G, Taylor S, Nelson M, et al. A global survey of HIV-positive people's attitudes towards cure research. *HIV Med*. 2017;18(2):73–9.
14. Dubé K, Evans D, Sylla L, Taylor J, Weiner BJ, Skinner A, et al. Willingness to participate and take risks in HIV cure research: survey results from 400 people living with HIV in the US. *J Virus Erad*. 2017;3:40–50.
15. Dube K, Evans D, Dee L, Sylla L, Taylor J, Skinner A, et al. We Need to Deploy Them Very Thoughtfully and Carefully: perceptions of analytical treatment interruptions in HIV cure research in the United States—a qualitative inquiry. *AIDS Res Hum Retroviruses* [Internet]. 2017 [cited 2017 Aug 14];(ja). Available from: <http://online.liebertpub.com/gate2.inist.fr/doi/abs/10.1089/AID.2017.0067>
16. Ma Q, Wu F, Henderson G, Rennie S, Rich ZC, Cheng Y, et al. I can coexist with HIV: a qualitative study of perceptions of HIV cure among people living with HIV in Guangzhou, China. *J Virus Erad*. 2016;2(3):170–4.
17. Moodley K, Staunton C, de Roubaix M, Cotton M. HIV cure research in South Africa: a preliminary exploration of stakeholder perspectives. *AIDS Care*. 2016;28(4):524–7.
18. Préau M, Doumergue M, Protière C, Goujard C, Mora M, Meyer L, et al. Perspectives on the acceptability of HCRC trials: the challenges for physicians and PLWHIV (ANRS APSEC). *AIDS Care*. 2018;30(7):914–20.
19. Fishbein M, Ajzen I. Belief, attitude, intention, and behavior: an introduction to theory and research. Reading, Mass: Addison-Wesley Pub. Co; 1975. 578 p.
20. Epstein S. The construction of lay expertise: AIDS activism and the forging of credibility in the reform of clinical trials. *Sci Technol Hum Values*. 1995;20(4):408–37.

21. Levine C. Has AIDS changed the ethics of human subjects research? *J Law Med Ethics*. 1988;16(3–4):167–73.
22. Carrera JS, Brown P, Brody JG, Morello-Frosch R. Research altruism as motivation for participation in community-centered environmental health research. *Soc Sci Med*. 2018;196:175–81.
23. Chanel O, Luchini S, Paraponaris A, Protière C, Vergnaud J-C. Les consentements à payer pour des programmes de prévention sanitaire incluent-ils de l'altruisme? Enseignements d'une enquête concernant la fièvre Q. *Rev Econ*. 2004;55(5):923–45.
24. Shiell A, Rush B. Can willingness to pay capture the value of altruism? An exploration of Sen's notion of commitment. *J Socio-Econ*. 2003;32:647–60.
25. Buchak L. Why high-risk, non-expected-utility-maximising gambles can be rational and beneficial: the case of HIV cure studies. *J Med Ethics*. 2017;43(2):90–5.
26. Protière C, Préau M, Carrieri P, Lambotte O, Spire B, Suzan-Monti M. Importance of the patient-physician interaction in assessing acceptability of HIV cure trials. *HIV Med* [Internet]. 2017 Jun 20 [cited 2017 Jun 21]; Available from: <http://doi.wiley.com/10.1111/hiv.12526>
27. Tucker JD, Rennie S. Social and Ethical Working Group on HIV Cure. Social and ethical implications of HIV cure research. *AIDS*. 2014;28(9):1247–50.
28. Grossman CI, Ross AL, Auerbach JD, Ananworanich J, Dubé K, Tucker JD, et al. Towards multidisciplinary HIV-cure research: integrating social science with biomedical research. *Trends Microbiol*. 2016;24(1):5–11.
29. Ryan M. Discrete choice experiments in health care. *BMJ*. 2004;328(7436):360–1.
30. Ryan M, Netten A, Skatun D, Smith P. Using discrete choice experiments to estimate a preference-based measure of outcome – an application to social care for older people. *J Health Econ*. 2006;25(5):927–44.
31. Bridges JFP, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health – a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. *Value Health*. 2011;14(4):403–13.
32. Bréigeeon-Ronot S, Cheret A, Cabié A, Prazuck T, Volny-Anne A, Ali S, et al. Evaluating patient preference and satisfaction for human immunodeficiency virus therapy in France. *Patient Prefer Adherence*. 2017;11:1159–69.
33. Aizaki H. Basic functions for supporting an implementation of choice experiments in R. *J Stat Softw* [Internet]. [cited 2017 Dec 7]; Available from: <https://www.jstatsoft.org/article/view/v050c02>
34. Campbell D, Erdem S. Including Opt-out options in discrete choice experiments: issues to consider. *Patient*. 2019;12(1):1–14.
35. Ryan M. Taking conjoint analysis to task. *Value Health*. 2011;14(4):401–2.
36. Veldwijk J, Lambooi MS, de Bekker-Grob EW, Smit HA, de Wit GA. The effect of including an opt-out option in discrete choice experiments. *PLoS ONE*. 2014;9:e111805.
37. de Bekker-Grob EW, Hol L, Donkers B, van Dam L, Habbema JDF, van Leerdam ME, et al. Labeled versus unlabeled discrete choice experiments in health economics: an application to colorectal cancer screening. *Value Health*. 2010;13(2):315–23.
38. Danhauer SC, Case LD, Tedeschi R, Russell G, Vishnevsky T, Triplett K, et al. Predictors of posttraumatic growth in women with breast cancer: post-traumatic growth and breast cancer. *Psychooncology*. 2013;22(12):2676–83.
39. Occhipinti S, Chambers SK, Lepore S, Aitken J, Dunn J. A Longitudinal study of post-traumatic growth and psychological distress in colorectal cancer survivors. *PLoS ONE*. 2015;10:e0139119.
40. Roux P, Marcellin F, Ndiaye K, Suzan-Monti M, Mayet A, Duracinsky M, et al. Posttraumatic stress disorder as a significant correlate of voluntary antiretroviral treatment interruption in adult HIV-infected patients followed up in French Hospitals: data from the ANRS-VESPA2 National Survey. *J Clin Psychiatry*. 2018;79(3):17m11659. <https://doi.org/10.4088/JCP.17m11659>.
41. Sagon-Teyssier L, Fressard L, Mora M, Maradan G, Guagliardo V, Suzan-Monti M, et al. Larger is not necessarily better! Impact of HIV care unit characteristics on virological success: results from the French national representative ANRS-VESPA2 study. *Health Policy*. 2016;120(8):936–47.
42. Suzan-Monti M, Lorente N, Demoulin B, Marcellin F, Préau M, Dray-Spira R, et al. Sexual risk behaviour among people living with HIV according to the biomedical risk of transmission: results from the ANRS-VESPA2 survey. *J Int AIDS Soc*. 2016;19(1):20095.
43. Insnard M, Sautory O. Les macros SAS d'analyse des données, document de travail Insee, n° F9405, 1994 Mar 15 [cited 2019 Feb 18]; 158 p. Available from: <https://www.insee.fr/fr/information/2021906>
44. McFadden D. Conditional logit analysis of qualitative choice behaviour. In: Zarembka P, editor. *Frontiers in econometrics*. New York, NY: Academic Press; 1974. p. 105–42.

45. McFadden D, Train K. Mixed MNL models for discrete response. *J Appl Econom*. 2000;15(5):447–70.
46. Fiebig DG, Keane MP, Louviere J, Wasi N. The generalized multinomial logit model: accounting for scale and coefficient heterogeneity. *Mark Sci*. 2009;29(3):393–421.
47. Lewin SR, Evans VA, Elliott JH, Spire B, Chomont N. Finding a cure for HIV: will it ever be achievable? *J Int AIDS Soc*. 2011;14(1):4.
48. Johnston R, Barré-Sinoussi F. Controversies in HIV cure research. *J Int AIDS Soc*. 2012;15(1):16.
49. Gianella S, Tsibris A, Barr L, Godfrey C. Barriers to a cure for HIV in women. *J Int AIDS Soc* [Internet]. 2016 Feb 18 [cited 2017 Oct 5];19(1). Available from: <http://www.jiasociety.org/index.php/jias/article/view/20706>
50. Jones RB. Current challenges and recent advances in the search for a cure for HIV. *J Int AIDS Soc*. 2019;22:e25248.
51. Bar-On Y, Gruell H, Schoofs T, Pai JA, Nogueira L, Butler AL, et al. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. *Nat Med*. 2018;24(11):1701–7.
52. Fromentin R, DaFonseca S, Costiniuk CT, El-Far M, Procopio FA, Hecht FM, et al. PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals. *Nat Commun*. 2019;18:814.
53. Uldrick TS, Gonçalves PH, Abdul-Hay M, Claeys AJ, Emu B, Ernstoff MS, et al. Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer – a phase 1 study. *JAMA Oncol*. 2019;5(9):1332–9.
54. Halper-Stromberg A, Lu C-L, Klein F, Horwitz JA, Bournazos S, Nogueira L, et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. *Cell*. 2014;158(5):989–99.
55. Delagrèverie HM, Delaugerre C, Lewin SR, Deeks SG, Li JZ. Ongoing clinical trials of human immunodeficiency virus latency-reversing and immunomodulatory agents. *Open Forum Infect Dis*. 2016;3(4):ofw189.
56. Xu L, Wang J, Liu Y, Xie L, Su B, Mou D, et al. CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia. *N Engl J Med* [Internet]. 2019 Sep 11 [cited 2019 Sep 18]; Available from: <https://www.nejm.org/doi/10.1056/NEJMoa1817426>
57. Tan DHS, Rana J, Fowler S, Hart TA, Wilton J, Bayoumi AM. Preferences regarding emerging HIV prevention technologies among Toronto men who have sex with men. Presentation in IAS 2017 in Paris. Paris, France; 2017. Abstract WEAC0102.
58. Salomon JA. Reconsidering the use of rankings in the valuation of health states: a model for estimating cardinal values from ordinal data. *Popul Health Metr*. 2003;1:12.
59. Mandel M. Simulation-based confidence intervals for functions with complicated derivatives. *Am Stat*. 2013;67(2):76–81.
60. Oehlert GW. A note on the delta method. *Am Stat*. 1992;46(1):27–9.

SUPPORTING INFORMATION

Additional information may be found under the Supporting Information tab for this article.

Table S1. Example of one of the 13 pairs of design comparisons

Table S2. Detailed results of the hierarchical clustering

Table S3. Description of four HCRCT candidates according to attribute levels

Table S4. Detailed results of the discrete choice experiment